| Literature DB >> 21954353 |
Rong Zheng1, Tuan-Sheng Chen, Tun Lu.
Abstract
The main functional components of green tea, such as epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG) and epicatechin (EC), are found to have a broad antineoplastic activity. The discovery of their targets plays an important role in revealing the antineoplastic mechanism. Therefore, to identify potential target proteins for tea polyphenols, we have taken a comparative virtual screening approach using two reverse docking systems, one based on Autodock software and the other on Tarfisdock. Two separate in silico workflows were implemented to derive a set of target proteins related to human diseases and ranked by the binding energy score. Several conventional clinically important proteins with anti-tumor effects are screened out from the PDTD protein database as the potential receptors by both procedures. To further analyze the validity of docking results, we study the binding mode of EGCG and the potential target protein Leukotriene A4 hydrolase in detail. We indicate that interactions mediated by electrostatic and hydrogen bond play a key role in ligand binding. EGCG binds to the enzyme with certain orientation and conformation that is suitable for nucleophilic attacks by several electrical residues inside the enzyme's activity cavity. This study provides useful information for studying the antitumor mechanism of tea's functional components. The comparative reverse docking strategy presented generates a tractable set of antineoplastic proteins for future experimental validation as drug targets against tumors.Entities:
Keywords: binding mode; reverse docking; target protein; tea polyphenols; virtual screening
Mesh:
Substances:
Year: 2011 PMID: 21954353 PMCID: PMC3179160 DOI: 10.3390/ijms12085200
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1.Structure of tea functional components EGCG, ECG, EGC and EC.
EGCG possible targets found by screening procedures compared with experiment.
| 3BCH | 67 kD laminin receptor | Autodock | YES | −3.75 | [ |
| 7HVP | HIV protease | Autodock/Tarfisdock | YES | −5.01/−44.87 | [ |
| 1GRE | glutathione reductase | Autodock | YES | −6.80 | [ |
| 1IJH | cholesterol oxidase | Autodock | YES | −6.77 | [ |
| 8CAT | catalase | Autodock | YES | −6.23 | [ |
| 1JNY | eEF1-α | Autodock | YES | −5.70 | [ |
| 1BOO | DNA methyltransferase | Autodock | YES | −4.66 | [ |
| 2OZO | ZAP-70 | Autodock | YES | −3.81 | [ |
| 2DQ7 | Fyn kinase | Autodock | YES | −4.91 | [ |
| 1HS6 | Leukotriene A4 | Autodock/Tarfisdock | NO | −5.22/−48.2 | Esophagus cancer |
| 1FT2 | Farnesyl protein transferase | Autodock/Tarfisdock | NO | −4.1/−44.94 | Cancer/Tumour |
| 1UTR | Mammalian PCB-binding protein | Autodock | NO | −7.19 | Lung Cancer |
| 1JVM | Voltage-Gated Potassium Channel | Autodock | NO | −6.58 | Cardiomyopathie |
| 1OG5 | CYP450 | Autodock | NO | −6.49 | Tumour |
| 1VKG | Histone deacetylase | Autodock | NO | −5.63 | Tumour |
| 1OOQ | Dihyrofolate reductase | Tarfisdock | NO | −46.42 | Tumour |
| 1IYH | Hematopoietic Prostagladin Synthase | Tarfisdock | NO | −44.50 | Cancer |
| 1PY5 | TGF-beta receptor type I | Tarfisdock | NO | −44.33 | Renal carcinoma |
Potential co-receptors of 4 types of Tea-polyphenols screened by Autodock.
| CYP450 | √ | √ | √ | √ |
| Oxidosqualene cyclase | √ | √ | √ | √ |
| Voltage-Gated Potassium Channel | √ | √ | — | √ |
| Phospholipase A2 | √ | √ | √ | √ |
| FK506 binding protein | √ | — | √ | √ |
| Dihyrofolate reductase | — | √ | √ | √ |
| Leukotriene A4 hydrolase | √ | — | √ | — |
| PARP(Poly ADP-Ribose Polymerase) | √ | √ | √ | — |
| Protoporphyrinogen oxidase | √ | √ | √ | — |
| Ornithine Aminotransferase | — | — | — | √ |
| 1,2-Cyclooxygenase | — | — | — | √ |
| histone deacetylases (HDACs) | — | — | √ | √ |
| Amino acid oxidase | — | — | √ | √ |
| Glutamic acid receptor-2 | — | √ | — | — |
| Mammalian PCB-binding protein | √ | — | √ | — |
| Fatty acid-binding protein (FABP) | √ | — | √ | — |
| Catalase | √ | √ | — | — |
The most possible targets screened by Autodock and Tarfisdock (top 3%).
| EGCG | 1HS6 | −48.21 | −5.22 | Leukotriene A4 hydrolase |
| 1FT2 | −44.94 | −4.10 | Farnesyl protein transferase | |
| 7HVP | −44.87 | −5.01 | HIV protease | |
| 1Y79 | −44.11 | −3.96 | Dipeptidyl peptidase | |
| EGC | 1YTV | −36.44 | −5.66 | Vasopressin V1a receptor |
| 1Q5M | −35.83 | −3.32 | Alpha hydroxysteroid dehydrogenase | |
| 1NR5 | −35.24 | −4.01 | 3-dehydroquinate Synthase | |
| 1Y79 | −35.19 | −3.77 | Peptidyl dipeptidase | |
| 2C6C | −48.27 | −3.31 | Glutamate carboxypeptidase II | |
| 1TCO | −43.82 | −6.07 | FK506 binding protein | |
| ECG | 1W6K | −38.06 | −6.07 | Oxidosqualene cyclase |
| 1HS6 | −46.21 | −5.74 | Leukotriene A4 hydrolase | |
| EC | 1W6K | −38.06 | −6.07 | Oxidosqualene cyclase |
Figure 2.The docked ligand BES compared with its original bound structure in crystallographic complex. It showed that the docked structure is very close to the experimental structure: Blue: original bound structure in crystal complex (left figure); Yellow: the docked conformation (right figure).
Figure 3.Micro environment of the bind site of EGCG/BES and Leukotriene A4 hydrolase. (a) EGCG (yellow) binds to Leukotriene A4 hydrolase in the active cavity (catalytic center and binding domain) where the original ligand BES (red) located; (b) Residues GLU348, SER380, TYR383, TYR378, ARG563, ARG565, ARG568, GLU296 and ARG537 make up a electrostatic cavity; hydroxyl groups of EGCG form hydrogen bonds with the surrounding amino acids GLU348, TYR383, GLU296 and ARG568 (blue); (c) The original ligand formed 3 strong hydrogen bonds with residues GLY269, ARG563, and ARG565 (orange).